CA3015080A1 - Whole-cell cancer vaccines and methods for selection thereof - Google Patents

Whole-cell cancer vaccines and methods for selection thereof Download PDF

Info

Publication number
CA3015080A1
CA3015080A1 CA3015080A CA3015080A CA3015080A1 CA 3015080 A1 CA3015080 A1 CA 3015080A1 CA 3015080 A CA3015080 A CA 3015080A CA 3015080 A CA3015080 A CA 3015080A CA 3015080 A1 CA3015080 A1 CA 3015080A1
Authority
CA
Canada
Prior art keywords
hla
gene
cell
allele
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3015080A
Other languages
English (en)
French (fr)
Inventor
Markus Daniel Lacher
Joseph Paul WAGNER
Charles Louis WISEMAN
William Valentine WILLIAMS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Briacell Therapeutics Corp USA
Original Assignee
Briacell Therapeutics Corp USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Briacell Therapeutics Corp USA filed Critical Briacell Therapeutics Corp USA
Priority to CA3300406A priority Critical patent/CA3300406A1/en
Publication of CA3015080A1 publication Critical patent/CA3015080A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/00112—Receptors for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3015080A 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof Pending CA3015080A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3300406A CA3300406A1 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662299674P 2016-02-25 2016-02-25
US62/299,674 2016-02-25
US201662425027P 2016-11-21 2016-11-21
US62/425,027 2016-11-21
PCT/US2017/019757 WO2017147600A1 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3300406A Division CA3300406A1 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof

Publications (1)

Publication Number Publication Date
CA3015080A1 true CA3015080A1 (en) 2017-08-31

Family

ID=59685619

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3015080A Pending CA3015080A1 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof
CA3300406A Pending CA3300406A1 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3300406A Pending CA3300406A1 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof

Country Status (9)

Country Link
US (2) US11559574B2 (https=)
EP (1) EP3419657A4 (https=)
JP (1) JP6901505B2 (https=)
CN (1) CN109069603A (https=)
AU (3) AU2017224232B2 (https=)
CA (2) CA3015080A1 (https=)
IL (1) IL261354A (https=)
NZ (1) NZ745327A (https=)
WO (1) WO2017147600A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147600A1 (en) 2016-02-25 2017-08-31 Briacell Therapeutics Corp. Whole-cell cancer vaccines and methods for selection thereof
CN111386042B (zh) * 2017-12-04 2023-01-31 热生物制品有限公司 基于细胞的疫苗的生产
JP2021507924A (ja) * 2017-12-22 2021-02-25 ディストリビューテッド バイオ， インコーポレイテッド 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法
CN108175853A (zh) * 2018-01-24 2018-06-19 上海赛群生物科技有限公司 一种肿瘤细胞疫苗及其制备方法
CN108486038B (zh) * 2018-03-21 2021-08-27 中国人民解放军第四军医大学 一种构建脂肪干细胞膜片的方法及应用
WO2020132595A1 (en) * 2018-12-21 2020-06-25 The Regents Of The University Of California Il-10-containing vaccines and uses thereof
TW202134430A (zh) 2019-12-03 2021-09-16 美商紐沃進公司 腫瘤細胞疫苗
CN110938630B (zh) * 2019-12-20 2023-07-28 中国人民解放军第四军医大学 人b3gnt5基因的用途及相关产品
WO2023092053A1 (en) * 2021-11-18 2023-05-25 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based cancer treatments
WO2023167973A1 (en) 2022-03-03 2023-09-07 Briacell Therapeutics Corp. Cancer vaccines and methods of use thereof
CN115433734B (zh) * 2022-06-01 2025-03-04 北京奇糖科技有限公司 核酸片段及其在制备肿瘤疫苗中的应用
CN117990593A (zh) * 2024-01-31 2024-05-07 南昌铭硕生科生物工程有限公司 一种流式多因子分析系统及其分析方法
WO2025171109A1 (en) 2024-02-07 2025-08-14 Briacell Therapeutics Corp. Cancer vaccines expressing post-translational modified antigens and methods of use thereof
CN118207320A (zh) * 2024-04-28 2024-06-18 复旦大学附属中山医院 Hla-c*04:01基因的新用途及检测试剂盒
CN118207319A (zh) * 2024-04-28 2024-06-18 复旦大学附属中山医院 Hla-a*03:04基因的新用途及检测试剂盒
WO2026068517A1 (en) * 2024-09-24 2026-04-02 Universiteit Gent Cancer immunotherapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105008A0 (en) * 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
WO2000050589A1 (en) * 1999-02-22 2000-08-31 Ludwig Institute For Cancer Research TYROSINE KINASE RECEPTOR EphA3 ANTIGENIC PEPTIDES
US20130052215A9 (en) * 2003-09-26 2013-02-28 Eckhard Podack Tumor vaccine
US7674456B2 (en) 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
WO2006081629A1 (en) 2005-02-04 2006-08-10 Stem Cell Australia Pty Ltd Adenoviral vectors comprising a nucleic acid encoding a mhc class i molecule and the use of such vectors in cancer therapy.
WO2006135454A1 (en) * 2005-06-08 2006-12-21 Saint Vincent Medical Center, A California Corporation Novel cancer cell lines and uses thereof
US20080020386A1 (en) 2006-03-29 2008-01-24 Medigen Biotechnology Corporation Methods and apparatus for genotyping
US7807186B2 (en) * 2007-01-17 2010-10-05 University Of Maryland, Baltimore County Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
US8969254B2 (en) * 2010-12-16 2015-03-03 Dana-Farber Cancer Institute, Inc. Oligonucleotide array for tissue typing
AU2012257377B2 (en) 2011-05-17 2017-09-07 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
WO2017147600A1 (en) 2016-02-25 2017-08-31 Briacell Therapeutics Corp. Whole-cell cancer vaccines and methods for selection thereof

Also Published As

Publication number Publication date
AU2017224232B2 (en) 2022-07-28
AU2017224232A1 (en) 2018-09-06
NZ745327A (en) 2023-06-30
US20190046624A1 (en) 2019-02-14
JP6901505B2 (ja) 2021-07-14
IL261354A (en) 2018-10-31
EP3419657A1 (en) 2019-01-02
AU2022259857A1 (en) 2022-12-08
US11559574B2 (en) 2023-01-24
AU2025205094A1 (en) 2025-07-24
JP2019507608A (ja) 2019-03-22
CN109069603A (zh) 2018-12-21
AU2022259857B2 (en) 2025-05-29
US20230277640A1 (en) 2023-09-07
NZ785587A (en) 2025-02-28
WO2017147600A1 (en) 2017-08-31
EP3419657A4 (en) 2019-11-06
CA3300406A1 (en) 2026-03-02

Similar Documents

Publication Publication Date Title
US20230277640A1 (en) Whole-cell cancer vaccines and methods for selection thereof
ES3042082T3 (en) Methods of making chimeric antigen receptor-expressing cells
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
US20220152176A1 (en) Cancer biomarkers for durable clinical benefit
US11740242B2 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
US20200108066A1 (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
US20200323905A1 (en) Methods and compositions for modulating the immune system
US20210254097A1 (en) Engineering of immune cells for ex vivo cell therapy applications
US20220298222A1 (en) Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN114457110A (zh) 一种敲除fut8基因的方法
Lacher et al. SV-BR-1-gm, a clinically effective GM-CSF-Secreting breast cancer cell line, expresses an immune signature and directly activates CD4+ T lymphocytes
US20240398831A1 (en) Compositions comprising small molecule regulators of tumor immunity and methods of using same
WO2022159720A2 (en) Methods to quantify rate of clonal expansion and methods for treating clonal hematopoiesis and hematologic malignancies
JP2025003730A (ja) 癌患者への免疫チェックポイント阻害薬の投与の有効性を予測するためのデータを収集する方法
JP2023515190A (ja) Ａｐｃ欠損がんの治療のための方法および組成物
CN118401562A (zh) 抗tnmuc1 gold car t细胞的组合物和方法
US20240327520A1 (en) Methods and compositions for pkc-delta inhibition and cancer immunotherapy
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy
WO2025122856A1 (en) Use of fibroblast growth factor receptor 3 mutations and tumor mutational burden to predict response to immunotherapies
WO2025029865A1 (en) Cd19-targeted car t cell therapy
Orlandella Understanding the Impact of Diet and Obesity on Anti-tumor Immunity and Therapeutic Efficacy in Kidney Cancer
HK40028190A (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
Khandelwal et al. Alemtuzumab for Steroid Refractory Acute Graft Versus Host Disease in Pediatric Patients: A Retrospective Review of 12 Patients Reveals a Response Rate of 83%

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220224

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240924

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241115

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250129

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250526

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250526

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250917

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202